Study of Levofloxacin and Cefoperazone-Sulbactam Utilization Cost on Patients with Mild and Moderate Corona Virus Disease- 2019
Studi Biaya Penggunaan Antibiotik Levofloxacin dan Cefoperazone-Sulbactam pada Pasien Corona Virus Disease-2019 Derajat Ringan sampai Sedang
DOI:
https://doi.org/10.53342/pharmasci.v9i1.316Keywords:
Covid-19, Antibiotic, Cost of medicineAbstract
Covid-19 is a highly infectious disease caused by SARS Cov-2. Antibiotics are sometimes given as therapy to patients when there is a secondary bacterial infection. The purpose of this study was to determine the treatment costs associated with using antibiotics Levofloxacin and Cefoperazone Sulbactam for mild to moderate COVID-19 patients at Bhayangkara H.S Samsoeri Mertojoso Hospital in Surabaya. For mild COVID-19 patients who receive levofloxacin antibiotic therapy, the total cost of treatment is IDR. 66,648,632 with a length of stay of 9 days. For patients with moderate degrees of COVID-19, the total cost of treatment is Rp. 81,339,295 with 10 days of hospitalization. For mild COVID-19 patients who receive cefoperazone sulbactam antibiotic therapy, the total cost of treatment is IDR. 81,401,005 with a length of stay of 11 days. For patients with moderate degrees of COVID-19, the total medical costs are Rp. 71,613,107 with 9 days of hospitalization. Based on the evaluation of research results, mild COVID-19 patients can receive levofloxacin antibiotic therapy, while moderate COVID-19 patients can receive cefoperazone sulbactam antibiotic therapy because it is cheaper and results in a shorter length of stay.
References
2. Adityo Susilo, C. M. (2020). Coronavirus Disease 2019: Tinjauan Literatur Terkini. Jurnal Penyakit Dalam Indonesia, 1-23.
3. Health, Conditions and Diseases. [update 19 Mei 2021; diunduh 12 Oktober2021].Tersediadi: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus
4. Andi Paluseri, F. Z. (2021). Analisis Efektivitas Biaya Penggunaan Antibiotik Levofloxacin dan Azithromycin pada pasien penderita corona virus disease-2019. 2-5.
5. Karen L. Rascati, P. (2014). Essentials Of Pharmacoeconomis. Texas.
6. ARNOLD, R. J. (2010). Phamacoeconomics From Theory to Practice. California: Taylor and Francis Group, LLC.
7. Indonesia, K. K. (2013). Pedoman Penerapan Kajian Farmakoekonomi. Jakarta.
8. Yelvi Levani, A. D. (n.d.). Coronavirus Disease 2019 (COVID-19): Patogenesis, Manifestasi Klinis dan Pilihan Terapi. Jurnal Kedokteran dan Kesehatan, 3-14.
9. Jeratallah Aram Dani, Y. M. (2020). Covid-19 Dan Perubahan Komunikasi Sosial. Communication Journal, 1-9.
10. Fernandez, B. A. (2013). Studi Penggunaan Antibiotik Tanpa Resep Di Kabupaten Manggarai dan Manggarai Barat – NTT. Jurnal Ilmiah Mahasiswa Universitas Surabaya, 2-17.
11. Pratiwi, R. H. (2017). Mekanisme Pertahanan Bakteri Patogen Terhadap Antibiotik . Jurnal Pro-Life, 1-12.
12. Hidayat, M. A. (2018). Cost Effectiveness Analysis Penggunaan Antibiotik Untuk Pasien Rawat Inap Demam Tifoid Di RSUD Bangil Tahun 2016. 43-109.
13. Indonesia, K. K. (2013). Pedoman Penerapan Kajian Farmakoekonomi.
Jakarta.
14. Khoiriyah, S. D., & Lestari, K. (2018). Review Artikel: Kajian Farmakoekonomi Yang Mendasari Pemilihan Pengobatan Di Indonesia. 2- 12.
15. Podder, V., & Sadiq, N. M. (2019). Levofloxacin. Tairunnessa Memorial Medical College and Hospital.
16. Yogesh Gupta, S. K. (2014). Fluoroquinolones: a Pharmaceutical Review.
International Journal of Pharmaceutical Science Invention.
17. Shahbaz, K. (2017). Cephalosporins: pharmacology and chemistry PHARMACEUTICAL AND BIOLOGICAL EVALUATIONS, 2-5.
18. https://www.nhlbi.nih.gov/health/pneumonia
19. Pneumonia Nosokomial. (2003). In Pedoman Diagnosis & Penatalaksanaan di Indonesia (pp. 8-17). Perhimpunan Dokter Paru Indonesia.
20. Farida, H., Herawati, Hapsari, M., Notoatmodjo, H., & Hardian. (2008). Penggunaan Antibiotik Secara Bijak Untuk Mengurangi Resistensi Antibiotik, Studi Intervensi di Bagian Kesehatan Anak RS Dr. Kariadi. 7-8.
21. Astiti, R. S. (2016). Cost Analysis Penggunaan Antipsikotik Pada Pasien Skizofrenia Poli Psikiatri di RSUD RA KARTINI JEPARA Tahun 2016. 14-46
